No increased prevalence of autoantibodies neutralizing type I IFNs in idiopathic pulmonary fibrosis patients

Quentin Philippot; Paul Bastard; Anne Puel; Jean-Laurent Casanova; Aurélie Cobat; Cédric Laouénan; Coralie Tardivon; Bruno Crestani; Raphael Borie

doi:10.1186/s12931-023-02396-4

No increased prevalence of autoantibodies neutralizing type I IFNs in idiopathic pulmonary fibrosis patients

Respir Res. 2023 Mar 20;24(1):87. doi: 10.1186/s12931-023-02396-4.

Authors

Quentin Philippot^{1

2}, Paul Bastard^{1

2

3

4}, Anne Puel^{1

2

3}, Jean-Laurent Casanova^{1

2

3

5

6}, Aurélie Cobat^{1

2

3}, Cédric Laouénan^{7

8}, Coralie Tardivon⁸, Bruno Crestani^{9

10}, Raphael Borie^{11

12}

Affiliations

¹ Laboratory of Human Genetics of Infectious Diseases, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children, Necker Branch, Paris, France.
² Imagine Institute, University of Paris, Paris, France.
³ St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, USA.
⁴ Pediatric Hematology-Immunology and Rheumatology Unit, Necker Hospital for Sick Children, Assistante Publique-Hôpitaux de Paris (AP-HP), Paris, France.
⁵ Department of Pediatrics, Necker Hospital for Sick Children, Paris, France.
⁶ Howard Hughes Medical Institute, New York, NY, USA.
⁷ Inserm, IAME, Université Paris Cité and Université Sorbonne Paris Nord, Paris, France.
⁸ Département d'Epidémiologie Biostatistiques et Recherche Clinique, AP-HP, Hôpital Bichat, Paris, France.
⁹ Service de Pneumologie A Hôpital Bichat, APHP, 46 Rue Henri Huchard, 75877, Paris CEDEX 18, France.
¹⁰ Inserm, PHERE, Université Paris Cité, 75018, Paris, France.
¹¹ Service de Pneumologie A Hôpital Bichat, APHP, 46 Rue Henri Huchard, 75877, Paris CEDEX 18, France. [email protected].
¹² Inserm, PHERE, Université Paris Cité, 75018, Paris, France. [email protected].

Abstract

SARS-CoV2 infection has a poor prognosis in patients affected of idiopathic pulmonary fibrosis (IPF). Autoantibodies (auto-Abs) neutralizing type I interferons (IFNs) are found in the blood of at least 15% of patients with life-threatening COVID-19 pneumonia. Because of the elevated prevalence of some auto-Abs in IPF patients, we hypothesize that the prevalence of auto-Abs neutralizing type I IFNs might be increased in the IPF population and then explained specific poor outcome after COVID-19. We screened the plasma of 247 consecutive IPF patients for the presence of auto-Abs neutralizing type I IFNs. Three patients displayed auto-Abs neutralizing type I IFNs. Among them, the only patient with documented SARS-CoV-2 infection experienced life threatening COVID-19 pneumonia. The prevalence of auto-Abs neutralizing type I IFNs in this cohort of IPF patients was not significantly different from the one of the general population. Overall, this study did not suggest any association between auto-Abs neutralizing type I IFNs and IPF.

Keywords: Autoimmunity; COVID-19; Idiopathic pulmonary fibrosis.

Publication types

Letter

MeSH terms

Autoantibodies
COVID-19*
Humans
Idiopathic Pulmonary Fibrosis* / diagnosis
Idiopathic Pulmonary Fibrosis* / epidemiology
Interferon Type I*
Prevalence
RNA, Viral
SARS-CoV-2

Substances

Autoantibodies
Interferon Type I
RNA, Viral

Abstract

Publication types

MeSH terms

Substances

Grants and funding